439 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
RELAPSED OR REFRACTORY (R/R) AML PATIENTS
I/C
CLAG REGIMEN, CLAG-M REGIMEN, CLAG COMBINED WITH ANY OTHER DRUGS REGIMEN, CLAG RELATED REGIMENS
O
OVERALL RESPONSE RATE (ORR), OVERALL SURVIVAL (OS), EARLY DEATH (ED), ADVERSE EVENTS
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
GNB suspected for carbapenemase production
I/C
Xpert Carba-R assay, Other methods of detecting carbapenemase genes in GNB
O
Accuracy of Xpert Carba-R assay in detecting carbapenemase genes in GNB
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Evolut R/Pro, Sapien 3
I/C
transcatheter aortic valve implantation (TAVI), Evolut R/Pro vs Sapien 3
O
all-cause mortality (short and long-term), stroke, bleeding, permanent pacemaker implantation (PPI), acute kidney injury (AKI), major vascular complication, device success, moderate-severe aortic regurgitation (AR), pressure gradients
P
health professionals (HPs)
I/C
formal R/S-training, physicians, nurses
O
belief in influence of R/S on patients' health, prevalence of formal R/S-training
P
HBV+ donors, HBV+ recipients
I/C
D+/R- heart transplantation, D-/R+ heart transplantation
O
fewer active hepatitis infections, lower hepatitis-related mortality, comparable survival at 1 y
P
adults with mitral regurgitation (MR)
I/C
3D endoscopic mitral valve surgery (3D-MVS), robot-assisted mitral valve surgery (R-MVS), totally thoracoscopic mitral valve surgery (T-MVS), small incision mitral valve surgery (M-MVS), traditional thoracotomy mitral valve surgery (C-MVS)
O
complications, MR, blood transfusion rate, operation time, chest drainage